Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World April 24, 2013 Phillip Broadwith	US sues Novartis over alleged kickbacks Novartis has used illegal payments to induce pharmacies to switch kidney transplant patients onto its immunosuppressant drug Myfortic (mycophenolate sodium), a US government lawsuit alleges.
Chemistry World October 1, 2013 Emma Stoye	Japan confirms Novartis clinical trial data fabrication Japan's ministry of health has concluded that studies based on clinical trials for Novartis's blood pressure drug Diovan contain manipulated data. It is now investigating whether the company has broken Japanese law by citing these studies to promote the product.
The Motley Fool August 30, 2010 Brian Orelli	Maybe Not a Blockbuster, But We'll Take It Novartis' newest addition, blood pressure medication Tekamlo, isn't going to rocket to the top of the 2020 best seller list, but it's still a nice addition nonetheless.
Chemistry World November 6, 2013 Laura Howes	Novartis to shut Horsham site Last year, the firm slammed the UK for the high cost of conducting clinical trials in the country, warning that business would leave unless more incentives were introduced to encourage firms to carry out R&D.
Chemistry World November 11, 2013 Sarah Houlton	Mis-selling lands J&J with $2.2bn fine Johnson & Johnson has been given a hefty fine in the US for mis-selling three drugs. The company, and its subsidiaries Janssen and Scios, will pay $2.2 billion.
The Motley Fool May 28, 2008 Brian Lawler	A Strange Novartis MS Drug Story Novartis gets approval for a drug with an interesting history.
Chemistry World May 21, 2014 Phillip Broadwith	Novartis enhances its focus with eyecare deal Swiss pharma major Novartis is continuing its quest to excel in a few specialist fields by licensing rights to US firm Ophthotech's lead candidate, Fovista, for wet age-related macular degeneration.
The Motley Fool June 7, 2006 Stephen D. Simpson	Novartis Can't Say No The Swiss drug giant signs more deals to boost its pipeline. Investors, here is a strong company in a weak sector that's still somewhat undervalued -- not exactly the worst story of the week.
The Motley Fool January 19, 2006 Stephen D. Simpson	Novartis Marches On While reported profits are masked by some charges, this Swiss drug company is still delivering the goods. Throw in a solid pipeline and a reasonable valuation, and the stock could still be worth a look for new money in the pharmaceutical space.
The Motley Fool January 20, 2005 Stephen D. Simpson	Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error.
Managed Care September 2007	Income Said To Influence Use of Generics An observational analysis of pharmacy claims collected from 2001 to 2003 finds that where a person lives and the socioeconomic implications of that location have a lot do with his use of generic drugs.
The Motley Fool November 11, 2010 Brian Orelli	ATTRACTing Clinical Trial Failure Let's not make it a habit, Novartis. Novartis is dropping development of lung-cancer treatment ASA404 after a second failed phase 3 trial.
The Motley Fool March 29, 2006 Stephen D. Simpson	Novartis Bulks Up Its Pipeline The Swiss drug giant once again pays up to add trial candidates to its portfolio. Investors, take note.
Chemistry World August 30, 2013 Laura Howes	Nice rules against Afinitor The National Institute for Health and Care Excellence (Nice), which evaluates treatments based on cost effectiveness, has confirmed that patients with advanced breast cancer will not be prescribed the Novartis drug Afinitor (everolimus).
The Motley Fool October 23, 2006 Brian Lawler	No Slowing Novartis The Swiss pharmaceutical company shows strength in nearly all its divisions. Novartis looks like a good investment for risk-adverse investors searching for a large-cap pharma stock.
Chemistry World November 14, 2013 Phillip Broadwith	Novartis sells off blood diagnostics division Swiss-based company Novartis has agreed to sell off its blood transfusion diagnostics unit to Spanish blood products specialist Grifols for $1.7 billion.
The Motley Fool July 15, 2005 Stephen D. Simpson	Novartis' Over-the-Counter Tonic Novartis' latest purchase suggests a commitment to making itself a well-rounded pharma giant. Future margins may not be as high as they once were, but if the company can produce a lot more cash flow, investors won't mind a bit.
The Motley Fool June 6, 2008 Brian Lawler	Nothing Can Stop Novartis! Swiss pharmaceutical giant Novartis has bucketloads of cash, and apparently, it isn't afraid to use them.
The Motley Fool December 19, 2006 Brian Gorman	Novartis Cuts in Line at the Drugstore Consolidation in pharmacy benefits management may leave Novartis most resistant to pricing pressure. Investors, take note.
Chemistry World April 2, 2015 Emma Stoye	Novartis accused of 'derailing' trials for cheap eye disease drug The British Medical Journal has accused pharmaceutical giant Novartis of deliberately hindering research into the use of anticancer drug Avastin (bevacizumab) to treat age-related wet macular degeneration.
The Motley Fool July 16, 2009 Brian Orelli	A Strong Dollar Can Hurt Novartis makes it through a hard quarter.
The Motley Fool July 17, 2007 Brian Lawler	Still Strong at Novartis For investors who are willing to filter the negative news and are patient enough to wait for recently launched branded compounds to help its top-line growth, Novartis is worth a look
The Motley Fool July 16, 2010 Brian Orelli	A Positive Sign for Pharma Earnings Season Strong first-half results drove Novartis to increase its sales guidance for the year.
The Motley Fool September 1, 2005 Stephen D. Simpson	Novartis Keeps Gorging Offering to buy the remainder of Chiron for $4.5 billion may up this company's execution risk over the next few quarters. Investors, take note.
The Motley Fool May 28, 2010 Brian Orelli	This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope.
The Motley Fool June 4, 2010 Brian Orelli	This Cancer Drug's on a Roll Novartis' Afinitor scores another win.
The Motley Fool April 21, 2005 Stephen D. Simpson	Novartis' Triple Threat The Swiss drug giant boasts strong franchises in generics, cardiology, and oncology. It's hard not to think of Novartis as one of the highest-quality options in the pharmaceutical investing space.
The Motley Fool April 4, 2007 Brian Lawler	Novartis Gets Nicked Novartis pulls one of its top-selling drugs from the market. Investors should come to expect drug delays or similar issues popping up from time to time when doing their analysis of large pharmas.
Chemistry World January 24, 2014 Phillip Broadwith	Novartis and DSM trim jobs Pharmaceutical firm Novartis and nutritional products specialist DSM are both set to cut jobs in Switzerland.
The Motley Fool July 21, 2004 Brian Gorman	Novartis Shows the Way It may be a model for other pharmaceutical outfits looking to improve productivity.
Chemistry World August 6, 2007 Victoria Gill	Novartis Loses Indian Patent Law Case Swiss drug firm Novartis has lost its legal case against the Indian government, who it had accused of 'unconstitutional' patent law practices. The ruling sets an important precedent that will cheer the flourishing generics market in the country.
The Motley Fool January 22, 2007 Brian Lawler	Another Busy Year in Store for Novartis Trying to place a value on Novartis is a tough thing to do now with so many important drugs awaiting regulatory review and its addiction to acquisitions and divestitures making financial comparisons between the years tough.
The Motley Fool December 9, 2009 Brian Orelli	Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little.
Pharmaceutical Executive June 1, 2014 Ben Comer	Take as Directed: From Force to Finesse in Promoting Adherence Healthcare players tout patient education and engagement as the keys to better drug adherence rates. Patients agree, as long as that translates to convenient and affordable access to therapy.
The Motley Fool March 16, 2005 Cliff Malings	Nice of You to Notice Novartis The Street finally pays attention to a longtime pharma winner on news of a major generic-drug acquisition.
BusinessWeek January 7, 2010 Capell & Doherty	What Novartis Sees in Eye Care Novartis CEO Dan Vasella's $50 billion bet on Alcon could help insulate it from the vagaries of the drug business.
BusinessWeek March 8, 2004 Arlene Weintraub	And When ImClone's Drug Doesn't Work... Physicians have greeted ImClone Systems Inc.'s (IMCL ) cancer drug, Erbitux, with a mixture of glee and grim realism. The drug dramatically shrinks colon tumors in some patients. But in others, it has little effect -- and no one knows why.
The Motley Fool August 17, 2009 Brian Orelli	Preparing for a Home Run Some good news and bad news for companies selling drugs to treat multiple sclerosis, after Novartis announces Extavia has been approved by the FDA.
BusinessWeek June 11, 2009 Kerry Capell	Novartis: Radically Remaking Its Drug Business CEO Dan Vasella's growth mantra for Novartis is follow the science, not the financials.
Pharmaceutical Executive October 1, 2005	Successful Alliances: Novartis and Idenix Share the Secrets of Success Novartis Pharma AG CEO Thomas Ebeling and Idenix founder, CEO, and chairman Jean-Pierre Sommadossi discuss the mutual benefits and challenges of maintaining a successful partnership.
Chemistry World February 15, 2007 Victoria Gill	Novartis Contests India's Patent Law Swiss pharmaceutical company Novartis has accused the Indian government of failing to comply with WTO rules after it refused to grant the company a patent on its cancer drug Glivec.
The Motley Fool January 20, 2010 Brian Orelli	Those Are Fighting Words Alcon's minority shareholders fight back.
The Motley Fool July 17, 2006 Stephen D. Simpson	Novartis Pays for Its Shopping Spree Expenses from the Chiron acquisition bring down results for the second quarter. Investors, there's a lot to be said for waiting on the right price for even the best stocks out there.
The Motley Fool April 8, 2008 Brian Lawler	Novartis Sees More Growth Ahead Novartis makes one of the largest acquisitions in health-care history.
The Motley Fool December 30, 2008 Brian Orelli	A Shot in the Arm for Novartis' Pipeline The company picks up the rights to a vaccine that fights a virus.
Pharmaceutical Executive December 1, 2006	Thoughtleader: Thomas Ebeling, Novartis The Next Big Thing: An interview with the pharma's CEO, who has witnessed tremendous financial and scientific growth at the company and is on the brink of his next major milestone.
The Motley Fool July 14, 2005 Stephen D. Simpson	These Swiss Don't Miss Aside from a hiccup in margins, Novartis' drug business continues to shine. This pharma is a solid middle-of-the-road play with reasonable valuation, a solid pipeline, and a not-so-secret weapon in its Sandoz generics business.
The Motley Fool March 3, 2011 Brian Orelli	3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year.
The Motley Fool October 31, 2005 Rich Duprey	Chiron Not Immune to Merger The board accepts a sweetened buyout offer from Swiss pharmaceutical firm Novartis. Investors, take note.
The Motley Fool June 7, 2004 Brian Gorman	Novartis Nabs Sabex Novartis' purchase gives it a lifeline to the generics market.